Truist raised the firm’s price target on CG Oncology (CGON) to $66 from $62 and keeps a Buy rating on the shares. The firm cites the company’s updated timeline for PIVOT-006 topline data, which is now expected in the first half of 2026 from 2027, the analyst tells investors in a research note. Truist further estimates peak revenue of about $1.4B for Creto in IR NMIBC – intermediate-risk non-muscle invasive bladder cancer – and a favorable setup, with surveillance as the control arm and a less crowded competitive landscape in IR NMIBC.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $82 from $55 at Goldman Sachs
- Top 5 Trending Stocks by Unusual Trading Volume, 1/10/26
- Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating
- Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology
- CG Oncology price target raised to $66 from $62 at Truist